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Abstract 
The important technological advance in genetic manipulation has led to the development of genetically modified animals. The resulting 
being is called a transgenic animal. This term refers to an animal, whose genome has been deliberately modified by transferring an 
exogenous DNA into all its cells, including the germinal ones. In 1981, GORDON and RUDDLE coined the term transgenic as an 
animal variant, result of the introduction of a gene, or genes, into its genome. More recently, there exists a tendency to use the term 
GMA (Genetically Modified Animal) to refer to transgenic animals.
Some arguments against the use of transgenic animals in research are related to the fact that during the creation of a transgenic 
animal its genetic integrity is not respected because of the recombination of genetic material from different species and even different 
kingdoms, as for example, animals and plants. Some people consider that this recombination of genetic material between species, 
or the creation of chimeras, which in occasions is a part of the technical strategy for the obtaining of a transgenic animal, alters the 
concept of “species”. In addition, they consider it as an unnatural intervention that might interfere in the conception of what makes that 
an animal is such. There is argued that the direct genetic modification is a mere extension of the traditional technologies of crossing. 
The genetic modifications of animals provide arguments for accusations as how to treat animals as things or merchandises.
Keywords: Transgenic animals, Biodiversity, Genetically modified organisms, Bioethics, Biotechnology, Recombinant DNA 
Resumen
El gran avance en tecnología para la manipulación genética, ha conducido al desarrollo de modelos animales modificados ge-
néticamente. Al ser resultante se le llama animal transgénico. Este término, se refiere a un animal cuyo genoma ha sido delibe-
radamente modificado, mediante transferencia de un DNA exógeno, en todas sus células, incluidas las germinales. En 1981, 
GORDON y RUDDLE acuñaron la palabra transgénico como una variante animal originada tras la introducción de un gen, o genes, 
en su genoma. Más recientemente se tiende a utilizar el término AMG (Animal Modificado Genéticamente) para referirse a los 
animales transgénicos.
Algunos argumentos en contra del uso de los animales transgénicos en investigación tienen que ver con una cuestión previa a su 
aplicación, como es que, en la creación de un animal transgénico, no se respeta la integridad genética de los animales ya que se 
produce la mezcla de material genético entre diferentes especies e incluso entre diferentes reinos, por ejemplo, entre animales y 
plantas. Algunas personas consideran que esta mezcla de material genético entre especies, o la creación de quimeras, que en 
ocasiones es parte de la estrategia técnica para la obtención de un animal transgénico, altera el concepto de “especie” y es una 
intervención antinatural que podría interferir en la concepción de lo que hace que un animal sea tal. Se argumenta que la modifica-
ción genética directa es meramente una extensión de las técnicas de cruzamiento tradicionales. Las modificaciones genéticas de 
animales proporcionan argumentos para acusaciones como tratar a los animales como cosas o mercancías.
Palabras clave: Animales Transgénicos, Biodiversidad, Organismos Genéticamente Modificados, Bioética, Biotecnología, DNA Recombinante
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Introduction
German Fritz Jahr proposed in 1927 the first construc-
tion of the word bioethics as an equation “Bio=Ethik”, 
in addition to a Bioethical Imperative, which also should 
consider other living beings in their related natural frames, 
together with the contributions given by wisdom. There 
has to be included artistic perspectives and/or the lived 
religion - constructed and experienced by historical, or 
anonymous prominent figures - in order to have guide-
lines of conduct that were able to protect life (Bios) as 
a whole, not only of human beings. All of this with the 
reverential respect towards life, within natural functioning, 
as it was proposed by the Noble-Peace-Prize-Winner A. 
Schweitzer (ROA-CASTELLANOS; BAUER, 2009).
More recently, POTTER (1970) methodologically propo-
ses in his article Bioethics, Science of Survival to inclu-
de ancient knowledge from the fields of philosophy and 
science, as well as renowned knowledge, as for exam-
ple empirical knowledge, exact sciences and books of 
the Holy Scriptures in order to establish guidelines of 
conduct that have allowed different human groups to 
survive. For POTTER, wisdom was a goal that would 
guarantee survival. But nowadays it can be perceived 
that the appreciation for each interlocutor has been 
more present in the real founders of bioethics, than in 
their legatees. This happens including with the so-called 
solver of moral medical problems, HELLEGERS (1971) 
that proposed the same neologism based on respect, 
even for the Georgetown school, though its proposal 
now has reduced for several years bioethics to its medi-
cal and legal problems. (CICCONE, 2006).
The term transgenesis developed in parallel designs 
the process of transferring genes in an organism. The 
transgenesis is used nowadays to create new plants and 
animals. Life as a meaning for some reason is not lon-
ger dignified or respected as an end by itself. There are 
different transgenic methods to modify cell reportoires or 
whole hosts, such as the use of pistols of genes or the 
use of bacteria or viruses as vectors to transfer the seg-
ments of genetic information (LACADENA, 1996).
Anyhow, the word transgenic refers to a plant or an animal 
into whose cells receive a fragment of exogenous DNA 
or DNA that cannot normally be found in the organism in 
question has been introduced. A transgenic mouse, for 
example, is one that has been injected with foreign DNA, 
through a fertilized-modified ovum that is implanted into 
an adoptive mother. The formed animal  has not only its 
own DNA, but also the fragment of exogenous DNA that 
was reinjected in the stage of fertilization of the ovum.
In this fashion, it is possible to study what effect this gene 
has on the whole organism instead of only observing 
a single cell in a cell culture. This is important because 
many diseases do not affect one single type of cells, but 
the interactions between many different types of cells, 
even the so-called stromal cells. This type of technolo-
gy allows exemplifying human diseases in other species, 
where it is possible to study the biology and possible 
therapies for the disease.
 
Transgenic animals
In the last decades, especially due to the huge advances 
in the knowledge of the molecular bases of diseases, 
there has appeared the need to have genetically defi-
ned models, that is, models in which the genetic muta-
tions that predispose, or take part in the development 
of the disease, could be controlled. This fact, together 
with the significant advance in technologies for genetic 
manipulation, has led to the development of genetically 
modified animal models, which are then called “transge-
nic animals”1. This term refers to an animal whose geno-
me has been deliberately modified by means transferring 
exogenous DNA into all its cells, including the germinal 
ones. In 1981, GORDON and RUDDLE coined the term 
transgenic as an animal variant, result of the introduc-
tion of a gene, or genes, into its genome.PALMITER and 
BRINSTER described in 1986 the introduction of genes 
into cells of the germinal line2.
The simplest form to generate a transgenic animal is the 
one that involves the isolation of the gene that shall be 
introduced (transgene), its cloning and manipulation, so 
that it can be expressed by target organism, as well as 
its insertion into the organism. To reach that all the cells 
of the organism express this new gene, it needs to be 
incorporated in an embryo, in a zygote stage or very 
early phases. Once the scientist is sure that the embryo 
incorporated the transgene, the new set of cells is im-
planted into a receptive animal, which acts as mother (in 
a procedure where is possible to use in vitro fertilization 
techniques).
If, on the other hand, one is not interested in an animal 
whose entire genome contains the transgene, but only 
certain type of its cells, a procedure similar to the pre-
viously described is being carried out, but instead of 
injecting the transgene into a zygote, it is injected, for 
example, into an already existing blastocyte. The result of 
this procedure is an organism with normal cells, as well 
as cells that contain the transgene.
1. More recently, there has been seen a tendency to use the term GMA (Genetically Modified Animals) to refer to transgenic animals.
2. The first transgenic laboratory mouse appeared in 1974 and was called Brinster´s Mouse; nowadays there exist approximately 1.000 strains of 
knockout mice. A knockout is a mutant animal which lacks the specific expression of a gene, eliminated by genetic mutation. The so-called knockin 
has a new gene included.
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An example of the use of this technology is the produc-
tion of transgenic sheep or goats. These are created by 
injecting the gene that codifies the desired protein into a 
fertilized ovum, which is implanted into a mother sheep 
or goat. Then, the presence of the desired gene in the 
offspring and those goats that present it, are induced 
to produce milk with some special characteristics when 
producing proteins.
The creation of transgenic animals presents new oppor-
tunities, but also creates new challenges. Among the first 
ones there is a possibility of studying the function of cer-
tain proteins, including some causes of human diseases. 
One of the major problems is the randomized insertion of 
the desired genes and the epistasis phenomena.
Animal transgenesis includes the addition (Knock in), 
substitution, elimination (Knock out) or inactivation of 
one, or multiple genes.Their applications include the 
area of basic investigation (creation of animal models 
for the analysis of animal and human pathologies, dis-
covery of new therapies, etc.), the food supply (impro-
vement of productive characters in livestock, resistance 
to diseases, etc.), the industry (synthesis of new textile 
compounds, therapeutic proteins, etc.) and the medicine 
(possibility of xenotransplants (PETROCELLI et al. 2003)3, 
models for gene therapy, etc.) amongst others that can 
be summarized as follows: 
• Genetic bases of diseases and therapy designs.
• Models for the investigation of infections and 
gene therapy.
• Models or bioreactors as basis for the testing of 
drugs and medicines.
• Biotechnological designs in agricultural industries.
• Animal models for the analysis of the effects of 
the modulation, activation or suppression of the 
gene expression.
The study of genetic syndromes, chronic metabolic disea-
ses, generation of new medicines to treat diverse diseases 
and the transplant of organs, are possibilities in transgene-
sis that should be deepened with respect to biological and 
ethical principles. The most common animals for this type 
of transplant are pigs, which, because of the similarities 
with the humans are the animals that show proportional 
size and if managed lowest rejection rates. 
In case of medicines, there are several advances from 
transgenic animals: insulin, growth hormone and anticoa-
gulant medicines are some of them.
Through the insertion of certain genes into mice, disea-
ses can be studied thoroughly, in order to know how they 
work.To test different treatments to find the best one, it 
is necessary to create transgenic mice that develop di-
fferent types of cancer. Nowadays these experiments 
have been mainly carried out in mice, though it can be 
expected to be done further with bigger animals, whose 
similarities with the humans are remarkable.
Besides, transgenic animals improve quantitatively and 
qualitatively certain elements as those in milk in the case 
of the cow-derived products, for enhancing human growth 
and the protection against diseases.
In the case of milk it is to be said that transgenic cows 
are able to generate lactose-free milk as well as enriched 
milk that can provide a major nutrition to babies and el-
ders4. There also exist transgenic hens that synthesize 
human proteins in the egg white of their eggs.
GMO - Derived food
The food products subjected to genetic engineering, 
also known as transgenic food, refers to products that 
were produced on the basis of a genetically modified or-
ganism by means of genetic engineering. In other words, 
it refers to food obtained from an organism to which ge-
nes derived from another organism have been added to 
the receptor in order to obtain desired characteristics. At 
present, there can be observed a major presence of food 
products coming from transgenic plants such as corn, 
barley or soybean.
The improvement of the species that would be used as 
food for mankind or domestic animals has been a com-
mon cause in the history of Humanity. Between 12.000 
and 4.000 b. C. there already existed the procedure of 
improvement by an artificial selection of plants. After the 
discovery of the sexual reproduction in vegetables, the 
first intergeneric crossing was realized in 1876. In 1909 
the first merger of protoplasts was carried out and in 1927 
there were obtained plant mutants of major productivity 
by means of X-ray irradiation of seeds. In 1983 the first 
transgenic plant was produced. In those days, some bio-
technologists manage to isolate a gene and to introduce 
it into a genome of the bacterium Escherichia coli.
Three years later, in 1986, Monsanto, a multinational bio-
technological company created the first genetically modi-
fied plant. It was tobacco plant, whose genome received 
a gene of resistance to the antibiotic Kanamicyn. Finally, 
3. Petrocelli, A; Rodríguez, D., Spadafora, C., Tamino, G.; Zannini, P. (2003).- Cap. 1; In Ravarotto, L; Pegoraro, R. (ed). Transgenesi, Clonazione, 
Xenotrapianto. Ed. Piccini. Padova
4. In Canada, some researchers did go further and used the genes of a spider in a goat, so that silk could be extracted from the milk of the latter.
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in 1994 the commercialization of the first genetically mo-
dified food, tomatoes FlavrSavr, created by Calgene, a 
biotechnological Company, was approved. An antisense 
gene was opposed to the normal gene of the poligalac-
turonase, an enzyme that leads to the ripeness of the 
tomato, so that it would remain live longer.
Nonetheless, few years later, in 1996, this product had 
to be withdrawn from the market of fresh products be-
cause of unforeseeable consequences such as a soft 
peel, a strange flavor and some other changes in their 
composition. Even so, these tomatoes are used for the 
production of elaborated tomatoes in industry.
Worldwide, the damages produced by weeds destroy 
almost 10 % of the crops. To avoid this, the farmers use 
herbicides with the resulting economic expense and 
contamination of water and soil. Generating plants that 
are resistant to these crops would improve this situation. 
To achieve it, vectors that transport genes of resistance 
to herbicides are transferred. An example of the afo-
rementioned, is the resistance to the herbicide glipho-
sate in the GMO soybean and corn. This substance is 
effective in low concentrations, but as chemical agent 
remains toxic for humans and the scavenging microor-
ganisms of the soil.
The action of the glyphosate is on the enzyme enolpyru-
vyl-shikimate-3-phosphate synthase (EPSP synthase), 
important for biosynthesis of amino acids, and there-
fore, by inhibiting this enzyme, the plant dies. The use 
of those organisms turns out to be a great problem 
since it would mean the development of “superunder-
growths”, due to the massive application of this herbi-
cide, which with after some time generates resistance 
in undergrowths (weeds), in addition to possible cros-
sings with similar non-transgenic plants. Many Latin-
American populations are in a situation of fight, due to 
the loss of the native corn and varieties cultivated in re-
mote times, that through policies are replaced by non 
replicative-GMO seeds, known as Terminator seeds. 
This type of technology try to prevent genetic mixture 
with wild types due to the high rate of crossing of this 
species since the way of dispersion of the pollen is the 
wind. However, this trait has been perversively used for 
economic purposes by attacking native-fitted varieties 
seen as competences for lab seeds. It is important to 
note this is not a scientific problem itself, but a problem 
of ethics in government agents and companies that 
allow such an unfair and anti-biodiversity use in times 
of environmental challange.
Nowadays, GMO corn and soybeans that are resistant 
to glyphosate compose the majority of raw material in 
markets of the USA and other countries (resistance ob-
served for the first time in 1996). Since it introduction to 
the market, there has been a spectacular increase in 
the development of crops of the transgenic soybean. 
Sadly, they are harvest on regions of tropical forests 
where worldwide flora and fauna have their refugee. 
Consequences, besides that damage, are losses of soil 
and erosion, due to the cultivation and lack of a post-
harvest-coverage. Similar things happened with the 
production of corn, cotton and rape (canoil) that also 
have had a high development rate at an almost equal 
level, but lower than the soybean. Of all these crops, the 
USA produces two-thirds of the worldwide production 
of GMO plant crops.
Nourishing along increasing 
qualities of crops
During the last 50-100 years, the genetic improvement 
of the plant cultures has resulted in an important impro-
vement of the productivity and increase in the nourishing 
capacities, but in the last years there has been decrea-
ses and even stagnation in the productive levels, which 
might be due to a lack of policies for soil protection. An 
example of cultures where biotechnology has helped to 
correct a nutritional deficiency is the one of golden rice, 
which shows increased levels of beta-carotene, a pre-
decessor of the vitamin A.The lack of this vitamin is a 
fact in many parts of Asia and Africa, where each year 
numerous children become permanently blind due to this 
deficiency. There has been detected a lack of nutrients in 
Latin America and the Caribbean. There are other studies 
that have been designed to increase the levels of fatty 
acids, of antioxidants and of other vitamins and minerals 
in the plant cultures (CAPÓ and DRANE, 2013). 
Transgenic plants and edible vaccines
Vaccines need a manufacturing process under contro-
lled condition. Nevertheless, in underdeveloped coun-
tries, there are problems regarding the production, trans-
port or storage of the vaccines since the majority of them 
need refrigeration and all of them need to be under sterile 
conditions. It is because of this that there are inexpen-
sive, synthesized vaccines that are being developed by 
synthesizing edible plants. GMO biotechnology may play 
a role for solving this situation. This way, the gene that 
codifies the antigenic subunit of the hepatitis B vaccine 
has been transferred to a tobacco plant and the same 
gene has been expressed in its leaves. In the same way, 
this technique is used to beat the cholera, as well as the 
use of other vegetables or fruit-plants as the potato or the 
banana that are being considered edible plants.
Nevertheless, considerations for the use of this tool it is 
understandable since what reaches our intestine is only 
the gene and not the complete virus or bacteria, there is 
no possibility that the person contracts the disease, but 
benefit is enough in order that our immune system reacts 
by protecting us against a possible infection.
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Transgenic tobacco plants 
for the decontamination of soils
In this case, the transgenic plants are used for the biorre-
mediation of soils. This study was carried out in a zone 
of a military training camp and firearm manufacturing site 
during the Second World War. The soil was poluted by 
residual TNT. To eliminate this problem, genetically modi-
fied tobacco plants have been planted. Those plants are 
capable of generating a major number of decomposing 
bacteria for this explosive without harmful elements.
Ethical aspects and processes
Scientists have admitted that science is not capable of 
predicting the whole set of risks and the impact obtained 
by the environmental release of genetically modified or-
ganisms. Therefore, transcendence of GMO release re-
mains unknown and it is uncertain which effect they have 
on biodiversity, human and animal health, environment, 
producing systems and even on food safety.
Science can originate, under parameters of rationality, 
technology that is intended to be essentially productive. 
Such a pretension, on the other hand, legitimates the use 
of knowledge (PFEIFFER, 2001). Technology sets out the 
following issues within its area of duties subjected to the 
principilist frame of bioethics, as follows:
• Enhancement tool for human regulation of na-
tural processes only through a moderate form 
and only if there is a need to do so - non- male-
ficence principle-.
• In a form that is reasonably useful for life, far 
away from conflicts of interest that can be de-
tected due to private business - beneficence 
principle-.
• In conformity with desired rational and logical will 
of all the affected stakeholders - rational princi-
ple of autonomy - and in an impartial way for all 
living dependant creatures - principle of justice-
Any person who is employed at a laboratory of molecular 
biology or genetic biology will affirm that there is no ethical 
problem in the production of genetically modified bacte-
ria or yeasts: they do not suppose any ethically relevant 
challenge beyond questions of biosafety. When these 
technologies came up, a moratorium regarding the use 
of these technologies took place. Back then, a series of 
experiments on DNA recombination was voluntarily pos-
tponed by the scientific community. This process ended 
with some ethical recommendations by Asilomar Confe-
rence regarding the issue in question.
The ethical challenges that arise due to genetically modi-
fied animals (GMA) are polyhedral since for the research 
and production of compounds for medical use, the use 
of the genetically modified animals is mainly being accep-
ted, as long as few regulations for the manipulation and 
treatment of those are respected. But when these gene-
tically modified organisms (GMO) are designed to pro-
duce tastier meat, the reticence grows and when GMOs 
of pets are created for capricious purposes, the ethical 
doubts increase.
For many researchers, the ethical problems of genetically 
irreversible modifications to invertebrate animals are non-
existent: the response is quite similar and the doubts are 
principally reduced to the problems of biosafety/biosecu-
rity. The doubts appear when there are plans of modifi-
cation in vertebrates and in the cases of animals close to 
the human phylogeny.
Concerns regarding the use 
of transgenics
The majority of the genetically modified products contain 
an introduced gene that codifies a protein that confers 
the desired character to the products (resistance to her-
bicide, to insects, etc.). Are there any environmental con-
sequences for our health because of this? 
In general, if the proteins are neither toxic nor allergic they 
do not have any negative physiological effect. In case of 
consuming the EPSP5 gene of resistance to herbicide 
together with the plant, it will degenerate rapidly.
In Europe, unlike in the USA, it is obligatory to label trans-
genic food. As for the risks, a constant debate exists due 
to a great disagreement about whether there is or not 
any type of risk. Until now, there is not a solidly proven 
theory regarding that since there is no scientific proof to 
demonstrate that transgenic crops by themselves do 
possess direct risk. Everything lies under suspicion since 
veiled interests are mutual accusations on used data. 
Intellectual Property
A frequently used argument against transgenic food is re-
lated to the management of the intellectual property rights 
and/or patents that force the farmers through market res-
trictions to pay royalties to the institutional improvement 
agent. In addition, some allude to the use of molecular 
3. Petrocelli, A; Rodríguez, D., Spadafora, C., Tamino, G.; Zannini, P. (2003).- Cap. 1; In Ravarotto, L; Pegoraro, R. (ed). Transgenesi, Clonazione, 
Xenotrapianto. Ed. Piccini. Padova
4. In Canada, some researchers did go further and used the genes of a spider in a goat, so that silk could be extracted from the milk of the latter.
5. Enzyme enolpyruvyl-shikimate-3-phosphate synthase (EPSP synthase).
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strategies that prevent the reutilization of the native to-
mato, that is, the employment of a part of the crop for 
cultivation in consecutive years. A known example of the 
latter aspect is the mentioned technology called Termina-
tor, included in those restrictions of use (GURT)6 , deve-
loped by the Department of Agriculture of the USA and 
the Delta and Pine Company during the decade of the 
1990s. This technology has not been incorporated yet to 
commercial crops and its sale is not yet authorized. The 
patent restriction operates for example by inhibiting the 
germination of seeds.
In this point, it is necessary to emphasize the use of the 
hybrid vigor, one of the most frequent strategies in plant 
improvement used in the non-traditional varieties. This 
procedure is based on the crossing of two lineages that 
act like parental lines, giving place to an offspring with a 
mixed genotype that possesses advantages as for quali-
ty, fitness, and agricultural performance.
As for the possibility of patenting transgenic plants, these 
they cannot be a patent eligible subject in strict sense, 
but can be subject of rights of the breeder, managed by 
the International Union for the Protection of new Varie-
ties of Plants (UPOV)7. From this perspective, transgenic 
plants are protected at a level that is equivalent to the 
one of the varieties generated by conventional procedu-
res. This fact necessarily demands the possibility of using 
varieties that are protected for agriculture survival and 
scientific research. In 2003, the UPOV declared about 
the technologies of restriction of use such as the pre-
viously mentioned Terminator the following: in agreement 
to the existence of a legal frame of protection of the new 
varieties, is indicated that the application of these tech-
nologies is not necessary.
On the initial issue, since the creation of transgenic ani-
mals is one of the current applications of the technology 
of the recombinant DNA, the analysis of its safety and of 
the ethical implications of its use is a part of the social 
debate and penetrates the barriers of scientific analysis.At 
this moment, the use of transgenic animals, or genetically 
modified animals represents one of the most powerful and 
complete tools of research of the biological sciences. This 
is therefore the leading cause because of which the hu-
man being should treat animals humanly: for the respect 
that it owes to itself as another being. Humans cannot de-
grade its dignity with a conduct that does not bear in mind 
the animal suffering, and/or put in peril its own survival.
Obviously, this conduct that respects the human digni-
ty implies that the human being adequately understands 
the value of the living creatures that allow his/her own 
life and that of the nature. Furthermore, mankind should 
understand the need to pass on to future generations a 
world in good conditions, without excessive degradation 
produced by its own selfish desire, but, surprisingly, the 
key point because of which the human being should do 
all of this is the maintenance of its own dignity.
As happens with other applications of this technology, 
our societies are debating two visions that are a prio-
ri opposites. On the one hand, there had never before 
existed a major ethical sensibility regarding the respect 
towards the use of other creatures. On the other hand, 
the applications of this technology reach fields that are 
of an enormous social and economic interest and their 
use can be converted into considerable benefits for the 
humanity in times future survival is questioned.
This double way is responsible for the presence of diffe-
rent sensibilities as for the use of the animals (transgenic 
or not). In this way, some defend the abolition of the use 
of animals on the basis of the rights of these organisms, 
whereas others defend that society is legitimized to use 
the animals, regardless of whether animals are consi-
dered to have rights or not. Survival acts as a bottom 
line in both cases. This debate, which is not exclusive 
for transgenic animals, serves nevertheless as frame for 
some arguments against its use, especially regarding its 
application to experimentation and lab animals.
There are arguments against the use of the transgenic 
animals in research related to an issue prior to its appli-
cation. For example, during the creation of transgenic 
animals the genetic integrity of the animals is not res-
pected since takes place a recombination of genetic 
material of different species and even different king-
doms (between animals and plants for example). Some 
consider that this recombination of genetic material 
between species, or the creation of chimeras, which in 
occasions is a part of the method, alters the concept 
of “species” and is an unnatural intervention that might 
interfere in the conception of what makes that animal. 
By thinking this way, questions arise, such as: What is 
the pig that possesses human genes for avoid trans-
plant rejection8?
6. Genetic Use Restriction Technologies.
7. The International Union for the Protection of new Varieties of Plants (UPOV) is an intergovernmental organization with headquarters in Geneva (Swit-
zerland); it was created by the International Convention for the Protection of New Varieties of Plants. The Agreement was adopted in Paris in 1961. Its 
mission is to provide and to promote an effective system for the protection of new varieties of plants, with respect to the development of new plant 
varieties for the benefit of the society. Brazil, Spain, Bolivia or Chile are in this union that counts with a total of 66 members in December of 2008.
8. Evidently, in order to be able to observe this difference between human beings and other animals and to affirm the superiority of the human being, 
it is necessary to depart from a series of observations that show the similarities and differences between the human being and other animals; in this 
respect, a reasonable description offers the chapter 2 of Fox MA. The Case for Animal Experimentation. An Evolutionary and Ethical Perspective. 
Berkeley and Los Angeles: University of California Press, 1986; 262.
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In response to these moral issues, it has been argued 
that in genetic engineering there is no recombination of 
genomes, but that there only are transferred one or two 
genes, a small fraction of the genome of the majority of 
the receiving species. That is why it is not possible to 
speak about “humanization” of the pig, when human ge-
nes are transferred to obtain a transgenic pig. “Humani-
zed strains”, however, is a word used in laboratories for 
those cases and individuals. In addition, it should not be 
ignored that many genes are preserved between diffe-
rent species, for what the presence of certain sequences 
does not seem to be determinant at the moment of defi-
ning the essence of a species.
As for the transgression of the barrier of species, and pro-
bable vulnerabilities towards infection agents, the discus-
sion is complex from a scientific point of view since the ba-
rrier of species is sometimes neither clear nor immutable.
One of the central criteria has always been the one of 
cost and benefit. That is one of the the basis for utilitarian 
ethics analysis. Not only in the economic sense, but in 
term of knowledge, this means, what kind of knowledge 
has been obtained at the cost of the sufferings inflicted 
to the laboratory animals. With this, the ethical balance 
should be set out - this unstable equilibrium between 
benefit and sacrifice - and there should be a constant 
search for alternative methods.
The well known three R´s, (RUSSELL AND BURCH, 
1959) correspond to the initial letters of three basic prin-
ciples that identify alternative methods9:
• Remplacement of the procedures that use animals 
by others that do not require them.
• Reduction of the number of animals used.
• Refinement of the methods used.
We as scientists consider that there should add a fourth 
“R”, which would be, at a personal level, the one of the 
scientist’s Responsibility10. According to Jonas “The hu-
man being is the only being known for having a sense of 
responsibility. Only human beings can choose consciously 
and deliberately between different alternatives of actions 
and this choice has its consequences.” (SIQUEIRA, 2001).
In addition, from another perspective, doing research with 
animals does generate high economic costs11; in many 
cases, this cost is provided by public funds. For that rea-
son, the insistence on futile experiments will find an addi-
tional criticism if it is done without enough racionality.
Thus, “It is perverse that the principal aim of certain ac-
tivists of animal rights is science, precisely the area in 
which there is major moral justification for the death of 
animals.” (BALLESTEROS et al., 2004). Professional 
knowledge and suitability, therefore, is indispensable to 
think in the most appropiate and convenient use of these 
alternatives for society.
Apart from the individual valuation with regard to the use 
of animals for food supply or for other uses related to re-
search or to industrial production, and independently of 
the moral consideration that one has on the manipulation 
of the animal genomes, it is important, from a global point 
of view, to indicate that the use of genetically modified ani-
mals, which is under a constant control12, is generating 
important scientific and sanitary benefits that in the future 
can produce significant applications of industrial interest.
It is necessary to indicate as well that, from a technical 
point of view, the current procedures of genetic modifica-
tions in animals as well as biotechnological procedures 
are supervised13.
At the moment, the use of transgenic animals, or GMO 
represents one of the most powerful and complete re-
search tools for the biological and medical sciences. 
The numerous possibilities of use of transgenic animals 
in very diverse fields of economic and scientific interest 
lead some researchers to think that the research with this 
type of animal is incompatible with the principle of re-
duction previously mentioned. To underline the fact that 
transgenic animals do not contribute to the reduction in 
the use of laboratory animals, here is some information: 
it is estimated that in the number of animals used for stu-
dies related to the creation and use of transgenics in-
creased by 73 % between 1997 and 1998 in Canada, 
by 29% in Great Britain and by 20% in the USA (GRIFFIN 
et al., 2009). Knock out organisms are also daily used in 
laboratories all around the world.
9. In 1986, by means of the Directive 86/609/EEC, the European Community urges its member states to promote the legislation concerning the 
“three R´s”, which is being done since then, however, with different diligences. Finally, the CE has created the European Centre for the Validation of 
Alternative Methods (ECVAM), located in Ispra, Italy.
10. The moral progress, which is the only progress to which we might aspire, relies on responsibility. Today, there is neither a person nor an insti-
tution that could take responsibility for the results of all this experimentation 20 years from now.
11. To start a research project, it is necessary to process a whole series of permissions and train all the staff involved in the project (animal carers, 
graduate staff and specially trained personnel).
12. Cartagena Protocol on Biosafety to the Convention on Biological Diversity. 29th of January of 2000.
13. Nagoya-Kuala Lumpur Protocol on Liability and Redress, supplement to the Cartagena Protocol. 2010.
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Studies which consider the evolution of the use of animals 
in different countries detect a similar situation: since 1996, 
there has been taken place a gradual decrease of the ex-
periments that generate severe pain in non- anesthetized 
animals in Great Britain, Canada and the USA. Techniques 
have been refined. Currently, the quota of reporting this 
type of procedure are at a scarce level (GRIFFIN, 2002) 
and society counts on Research and Ethics Comittees to 
make sure animal experiments are rightly perfomed. Ne-
vertheless, though the use of mice was decreasing gra-
dually from 1991 to 1997, from then on, a progressive 
increase is being detected, coinciding with the increase 
in the use of the transgenic animals. The relevancy of 
this increase detected in mice turns out to be clear if one 
bears in mind that the rodents (mice and rats) constitute 
the group most extensively used as laboratory animals: in 
1999, for example, rodents counted for85 % of the total of 
laboratory animals used in Europe.
Therefore, the information on the use of animals seems to 
indicate that until the mid 1990s, the effort to reduce the 
number of animals used for research made by the gover-
nments was turning out to be really effective, but from this 
date, and coinciding with the development of the genetic 
modification in animals, there has taken place an impor-
tant change in this reductionist trend. A different necessity 
created a different demanding for lab animals.
The increase in the use of animals for research that inclu-
de procedures of genetic modification are linked to the 
fact that they constitute models to study the detailed mo-
lecular mechanism of pathologies, and on the other hand, 
to the fact that in order to obtain transgenic mutants, a 
great number of animals that are rejected for not presen-
ting the appropriate geno or phenotype (they do not show 
the specific characteristics that are required), or because 
they are not allowed to live. In many occasions a large part 
of transgenic animals do not survive over a long period of 
time from their birth, since the physiological and anatomi-
cal defects are directly derived from the introduction of the 
new gene are too significant. Also, these animals by law 
have to be destroyed once used.
Moreover, transgenetic technologies show a low-level of 
efficiency in many experiments and many of the animals 
used for the process die early during the embryonic de-
velopment or due to anatomical, physiological or behavio-
ral defects. In some occasions the transgenetic process 
leads to the appearance of unexpected phenotypes, due 
to a limited control of the technology of insertion of genes 
or due to unexpected interactions of the introduced DNA 
with other genes of the animal used (background or gene-
tic pool). As an example, depending of the methodology 
used, the creation of a strain of transgenic mice in the year 
2000 required an average of between 365 and 900 mice 
(HUGHES, 2001). Certainly, technologies have slightly im-
proved since then, but the obtaining of a transgenic animal 
does still cause the “loss” of a high number of animals.
Once “founded” a strain of a transgenic animal, the subse-
quent animals are created by means of conventional cros-
sing methods, in order to obtain animals that are going to 
be used for future experiments. 
Moreover, in relation to the second “R”, refinement, the 
situation gets complex. Technologies of genetic modifica-
tion, as will be shown, are increasingly precise in means of 
the insertion of genes. This is why the unwanted effects of 
the process of insertion, at least in some species, are get-
ting easier to avoid. But random insertion is a persistent de-
leterious effect stilla for many transgenic techniques. Those 
animals are prone to have additional health vulnerabilities.
 The use of the genetic modification is associated with the 
search for phenotypical effects that are easily detectable 
by the researcher, effects that usually are being associa-
ted with the presence of important anatomical, histological 
and physiological alterations, etc. In this respect, one of 
the most frequent and interesting applications, from the 
scientific point of view, is the creation of the previously 
mentioned transgenic knock-outs, those are, animals in 
which a functional gene is replaced with a non-functional 
version by means of homologeous recombination. This 
type of site-directed mutagenesis by deletion produces 
the absence of a certain functional gene product. This te-
chnology has been especially developed and applied to 
mice with the aim of creating models of human and animal 
neoplasic diseases. In these situations in which the disea-
se is “created”, the animals undoubtedly suffer to some 
degree (MEMPHAM et al., 1999).
It is questionable whether it is appropriate to apply the tech-
nology of genetic modification to specifically generate ani-
mals that experience a disease that in many cases usually 
would not break out in this species under natural conditions. 
Certainly, there might be discussed if the suffering ge-
nerated by a “created” pathology in an animal model is 
unnecessary or not, or if it is necessary to be relieved of 
a iatrogenic process, but what is clear is that for health 
personnel it is a “must” to cure, if possible,, unless one 
previously decides not to “generate” the above-mentioned 
animal model. Sadly, slaughter is the most frequent end 
for paradoxically avoiding transgenic genes spread.
As for the importance of the genetically modified animals, 
there are two aspects that must be considered in the third 
“r” of reemplacement. On the one hand, the possibility 
of creating animal models in species as the mouse, gives 
the opportunity to reduce the use of non-human primates 
in some types of clinical trials, for example, the clinical trial 
of the polio vaccine (GORDON, 1997), in research on neu-
rodegenerative diseases (CHAN, 2004), on viral infections 
such as hepatitis B, HIV, etc. On the other hand, the develo-
pment of new technologies for the gene inactivation, as the 
interference RNA (RNAi), enables to think about alternative 
methods that in the near future could replace some experi-
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ments that nowadays are carried out in mammalian knock-
outs, such as clinical trials of gene silencing in cultures of 
stem cells or differentiated cells (HASUWA, 2002), or clinical 
trials carried out in non-mammalian animals for which the 
methodology of homologous recombination has not been 
developed up to the moment (ROIGNANT et al., 2003).
It is possible that the numerous scientific and biotechnolo-
gical possibilities of the genetic modifications (studies on 
gene regulation, physiological research, production of pro-
teins or specific hormones, clinical trials on toxicity of medi-
cines, improvement of growth and of quality in agriculture, 
etc.) lead to an explosion, maybe temporarily, in its use. It is 
important to indicate that the justification for this explosion 
in the use of transgenic animals on the basis of the po-
tential benefits that derive from their use, is a point of view 
that belongs to the area of the so-called “utilitarian ethics”, 
which, nevertheless, is not shared by the whole society.
The characters introduced by means of genetic enginee-
ring in species destined to the production of edible pro-
ducts contribute to an increased productivity (for example 
by means of a major resistance to plagues) as well as 
the introduction of new characteristics of quality. Due to 
the major development of the genetic manipulation in plant 
species, all GMO food products correspond to derivatives 
of plants. A frequently used characteristic is, for example, 
the resistance to herbicides, as it is possible to use them 
in a way that they only affect the flora alien to the crop. 
It is to be emphasized that the employment of modified 
varieties that are resistant to herbicides has diminished 
the pollution due to the presence of these products in 
aquiferous and soils, though it is true that there would be 
no need for the use of these herbicides, which are very 
harmful because of their content of glyphosate (GLY) and 
ammonium glyphosinate (GLU) if these varieties were not 
planted, which are exclusively designed to resist to the 
above-mentioned compounds.
Insect pests are one of the most devastating elements in 
agriculture. For this reason, the introduction of genes that 
provoke the development of plants that are resistant to 
one or more insect orders has been a common element 
of many of the patented varieties. The advantages of this 
method leads to a minor use of insecticides in the fields 
sowed with these varieties, which results in a minor impact 
to the ecosystem that harbors the crops and to the health 
of the workers that manipulate the phytosanitaries.
Ultimately, the first transgenic animals are being develo-
ped. The first transgenic animal that has been approved 
for human consumption in the USA was a salmon called 
Aqua Bounty (2010)14, which was capable of growing twi-
ce as fast and also during the winter, thanks to the growth 
hormone of another species of salmon and the “antifree-
ze” gene of another species of fish.
In several countries of the world there have appeared 
groups opposed15 to the creation of transgenic orga-
nisms, principally made up of ecologists, associations that 
promote consumer rights, as well as some scientists and 
politicians. Those demand the labeling of genetically mo-
dified organisms since they worry about food safety, envi-
ronmental impact, cultural changes and economic depen-
dences that could arise from the use of these products. 
They invoke to avoid this type of food, whose produc-
tion would involve damages to health, as well as environ-
mental, economic, social damages and legal and ethical 
problems due to patent restrictions. Thus, the advanta-
ges and disadvantages of the process need to be taken 
into account. That is to say: the beneficial impact as for 
economy, environmental status of the near-crops ecosys-
tem and on the health of the farmer should be taken into 
account, as previously described, as well as doubts with 
regard to the possible appearance of allergies, changes in 
the nutritional profile, dilution of the genetic array and the 
diffusion of resistances to antibiotics.
The Food and Agriculture Association (FAO) indicated the 
following with regard to the transgenics whose purpose is 
to serve as food supply: The countries in which transgenic 
crops have been introduced to fields have not observed 
notable damages to health or environment. In addition, the 
farmers use fewer pesticides or less toxic pesticides, re-
ducing in this way the pollution of the water supplies and 
the damages to the health of the workers, allowing also 
the return to the fields of beneficial insects. Some of the 
concerns related to the flow of genes and the resistance 
to plagues have been approached thanks to new techno-
logies of genetic engineering.
Nevertheless, that there have not been observed negative 
effects until now, does not mean that could not exist in the 
future. Many scientists request a careful case-by- case 
evaluation, before the product or process can be spread, 
in order to face the legitimate safety concerns.
The elimination of living autochthonous varieties due to 
the use of genetically improved populations, diminish the 
genetic range and the biodiversity for other characteristics 
that can be brought together with the selected characteris-
tics. If one considers, in addition, the induced reproduction 
impossibility of certain populations or the lack of observa-
tion of other biological characteristics beyond the aim of 
the study, the damage is profound at an ecological level.
The World Health Organization indicates in this regard that 
the different genetically modified organisms (GMO) include 
different genes inserted in different ways. This means that 
14. Aqua Bounty is a biotechnological company dedicated to research, the development and the commercialization of products that are intended 
to increase the productivity of the fish farming.
15. There was a protest by Spanish agrarian organizations against the use of transgenics in the ecological agriculture (Puerta del Sol of Madrid, on 
the 30th of August of 2008).
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each genetically modified food (GM) and its innocuousness 
need to be evaluated individually and that is not possible 
to make generalized statements on the innocuousness 
of all genetically modified food. The genetically modified 
food that is nowadays available on the international market 
passed the risk assessments and it is not probable that 
they present risks to human health. In addition, there have 
not been demonstrated effects on the human health as a 
result of the consumption of the above-mentioned food by 
the general population, in the countries where they were 
approved. The constant use of risk assessments accor-
ding to the principles of the codex and, where applicable, 
including the post-commercialization monitoring, need to 
be the base to evaluate the innocuousness of the geneti-
cally modified food.
This way, some arguments against the use of transgenic 
animals in research are related to an issue prior to its appli-
cation, such as during the creation of a transgenic animal, 
the genetic integrity of the animals is not respected since 
there takes place a recombination of genetic material of 
different species and even different kingdoms (between 
animals and plants for example). Some consider that this 
recombination of genetic material between species, or the 
creation of chimeras, which in occasions is a part of the 
technical strategy for the obtaining of a transgenic ani-
mal, alters the concept of “species” and is an unnatural 
intervention that might interfere in the conception of what 
makes that an animal is such. By thinking this way, ques-
tions arise such as what makes that a pig is such in the 
case that it possesses human genes.
To conclude, there is argued that the direct genetic modi-
fication is merely a tool. It can be harmful or benefical; It is 
a mere extension of the traditional and biological technolo-
gies of crossing, so that if genetic modifications of animals 
provide arguments for accusations such as “playing God”, 
“unnatural” or “to treat to the animals as goods”, the same 
arguments would be applicable to the selective crossings 
that are used in a routine way (BOYD GROUP, 1999)16.
16. Boyd Group is a forum for the exchange of points of view on questions of interest related to the use of laboratory animals.
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